Thompson Scientific produces report on generics market
PHILADELPHIA and LONDON Thomson Scientific has released the first issue of Movers and Shakers, a report analyzing the U.S. generics market from July to September 2007, as well as profiling some of the companies breaking into the market, and highlighting molecule patents currently being challenged.
Some of the highlights of the inaugural report were identifying key indicators of the industry like, abbreviated new drug applications and paragraph IV challenges. The report also released the names of some new companies entering the generics market like, Dabur India, who launched a paragraph IV challenge on the drug oxaliplatin, which is a drug used for chemotherapy and marketed under the brand name Eloxatin.
“Because of the dynamic nature of the generics market in the U.S., the common perception is that the market is relatively easy to break into,” said Kate Kuhrt, director, Generics and API Intelligence, Thomson Scientific. “However, our research has shown that there is huge competition between the incumbents and new companies vying for a slice of the market, and clearly there will be winners and losers. Ours is the first quarterly report to identify the real ‘movers and shakers’ within the generics market.”
Internet pharmacies make false claims regarding certification
SOUTH FLORIDA Federal regulators are receiving complaints from the Better Business Bureau and other professional groups after discovering that some Internet pharmacies are falsely claiming to be certified by their organizations, according to South Florida’s Sun-Sentinel.
The pharmacies are stating that they are located in Canada and are therefore offering cheaper prices on drugs to its customers, many of whom are Florida’s elderly. Customers started complaining after they wither did not receive their medications or they got drugs that appeared questionable.
One of the companies that the Internet pharmacies claim to be certified by is PharmacyChecker.com. Over the last 18 months, PharmacyChecker has received about 100 complaints from customers who thought they certified the websites.
The Internet pharmacies are using fake logos and phone numbers to make them appear certified and legitimate to customers. The Canadian International Pharmacy Association, which has 25 member pharmacies that are government-licensed, has also been receiving several calls a week from American consumers about not receiving shipments from sites they thought were CIPA-approved.
The Federal Bureau of Investigation has started a special investigation of Internet pharmacy practices, including the trademark violations and other issues.
Amylin launches SymlinPen for Type 2 diabetes
SAN DIEGO Amylin Pharmaceuticals has released its new prescription device, the SymlinPen 120 and 60 pen-injector devices for administering the blood sugar controlling drug Symlin. The new devices feature simple, fixed dosing to improve mealtime glucose control.
The SymlinPen 120 features fixed dosing to deliver 60 or 120 micrograms of Symlin per dose. The SymlinPen 60 features fixed dosing to deliver 15, 30, 45, or 60 micrograms of Symlin per dose. Both pen-injector devices can be conveniently stored at room temperature not to exceed 86 degrees F after first use.
“Symlin offers enhanced blood glucose control with potential weight loss for patients with diabetes using mealtime insulin, enabling them to do more to manage their diabetes,” said Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals. “The convenience of the new SymlinPen with simple, fixed dosing will make it easier for these patients using multiple daily injections to start and stay with Symlin.”